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Abstract
Background: For endoscopic interventions, heparin bridging therapy is recommended in patients who are at high
risk from interruption of antithrombotic therapy. Although heparin bridging has been reported to be effective in
preventing thrombosis, several reports have raised concerns about increased risk of bleeding. The aim of this study
was to clarify complications of hepari bridging therapy in therapeutic endoscopy.
Methods: A nationwide multicenter survey using questionnaire was performed about patients undergoing
therapeutic endoscopy with heparin bridging. Patients who underwent therapeutic endoscopy without heparin
bridging therapy were considered as controls. Compliance scores of heparin bridging therapy guideline were
employed, and association was analyzed between the score and occurrence of post-procedural bleeding.
Results: The incidence of post-procedural bleeding was significantly higher (13.5 %, 33/245) in the heparin group
compared with the control group (2.7 %, 299/11102)(p < 0.001). Thrombosis occurred in 1 patient each in the two
groups. In the heparin group, post-procedural bleeding was more likely to be delayed bleeding. Dose adjustment
of heparin was a significant factor contributing to bleeding. The compliance score of heparin bridging therapy
guideline was significantly higher in those who suffered bleeding.
Conclusions: Heparin bridging therapy significantly increased the risk of post-procedural bleeding compared with
the control. The bleeding risk was associated with greater adherence with guidelines for heparin bridging therapy.
Keywords: Endoscopic treatment, Post-procedural bleeding, Thrombosis, Antithrombotic therapy
Background
Antithrombotic therapy with antiplatelet or anticoagu-
lant agents is widely used for the primary and secondary
prophylaxis of cardiovascular and cerebrovascular disor-
ders, and patients using oral antithrombotic agents have
been increasing worldwide.
Conventionally, guidelines recommended temporary
interruption of antithrombotic therapy for endoscopic
interventions [1]. Recent guidelines emphasize the im-
portance of thrombosis prophylaxis and recommend
not to interrupt antithrombotic therapy as long as pos-
sible [2, 3].
Heparin bridging therapy(HBT) has been a strategy
conventionally used for patients requiring interruption
of antithrombotic therapy but at high risk from the
interruption of antithrombotic therapy, whether antico-
agulants or antiplatelet agents. According to recent
guidelines, for those receiving antiplatelet therapy, HBT
is not recommended and antiplatelet therapy should be
continued with low-dose aspirin during the peri-
procedural period [2, 3]. For those receiving warfarin,
however, its interruption has been reported to lead to
potentially fatal serious thrombosis in 0.6 % to 1.0 % of
cases [4–6]. Thus, HBT remains recommended for
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patients on oral anticoagulant therapy who are at high
risk from interruption of the therapy [2, 3, 7–9].
While some manuscripts reported the effectiveness of
HBT in preventing thrombosis, others describe an in-
creased risk of bleeding during HBT [10–12].
The present study was conducted to clarify complications
of HBT in patients undergoing therapeutic endoscopy,
which is classified among endoscopic procedures posing
a high risk of bleeding.
Methods
A nationwide multicenter survey with questionnaire was
performed in Japan, about patients who received HBT in
therapeutic endoscopy (Fig. 1).
Fig. 1 Questionnaires
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This survey had been performed in accordance with
the Declaration of Helsinki and had been approved in
the Ethics Committee of Hokkaido University Hospital
(IRB No. 012–0093).
Patients and therapeutic endoscopy
Subjects were successive patients who underwent a
therapeutic gastroscopy or colonoscopy using HBT at
participating institutions between April 2009 and March
2011. Evaluated anticoagulants were limited to warfarin
and dabigatran which were available oral anticoagulants
during the study period in Japan.
Inclusion criteria was following endoscopic interven-
tions; gastric endoscopic mucosal resection (EMR) and
endoscopic submucosal dissection(ESD), and colon poly-
pectomy, EMR and ESD.
The interventions for esophagus, duodenum and small
intestine, percutaneous endoscopic gastrostomy(PEG),
and billio-pancreatic therapy were excluded.
The manner of each endoscopic treatment followed
the guideline of Japan Gastroenterological Endoscopy
Society.
Survey items
The following data were collected by retrospectively
reviewing the medical records; age, sex, specific oral an-
tithrombotic drugs (anticoagulants including warfarin,
dabigatran, antiplatelet drugs including aspirin, clopido-
grel, and cilostazole), primary disease as an indication
for antithrombotic therapy, type of heparin used, any
dose adjustment of heparin, any coagulation tests and
their data around the time of heparin use, and timing of
the resumption of chronic antithrombotic therapy. Dose
adjustment of heparin was defined as administration of
heparin at an adjusted dose according to the activated
partial thromboplastin time (APTT). No dose adjust-
ment of heparin referred to administration of heparin at
a fixed dose irrespective of the APTT.
Data on complications were collected in terms of the
following: presence or absence of any complications
(post-procedural bleeding and thrombosis) occurring
between the interruption of antithrombotic therapy
and two weeks after the therapeutic endoscopy, timing
of its occurrence, presence or absence of treatment for
the complication, and details of treatment if any. Post-
procedural bleeding was defined as bleeding that oc-
curred after therapeutic endoscopy and met any the
following criteria: (1) apparent post-procedural hema-
temesis or melena requiring emergency endoscopic
intervention or open surgery; (2) Forrest grade Ia or Ib
bleeding noted on a follow-up endoscopic evaluation;
or (3) bleeding requiring blood transfusion.
Controls were patients who underwent therapeutic en-
doscopy without HBT at the same participating medical
institutions during the same period as above. Data on
controls were collected in terms of the number of thera-
peutic endoscopies, and the numbers of patients with
post-procedural bleeding and thrombosis.
Participation institutions
Among all the coaching institutions of Japan Gastro-
enterological Endoscopy Society that are known to per-
form therapeutic endoscopy, 22 were contacted and 17
institutions agreed to participate in the study.
Endpoints
The primary endpoints were the incidences of post-
procedural bleeding and thrombosis among patients
who underwent therapeutic endoscopy on HBT. The
secondary endpoints were factors contributing to bleed-
ing, timing of bleeding, and association between heparin
bridging guideline compliance scores and occurrence of
post-procedural bleeding.
Compliance scores
Compliance scores of HBT guideline were employed to
measure whether appropriate bridging was performed.
For the scoring, in patients who received heparin bridg-
ing during interruption of their chronic anticoagulant
therapy, the following items were assessed according to
guideline recommendations:
(1) the duration of pre-procedural interruption of war-
farin therapy, 3–5 days; (2) APTT during heparin bridg-
ing, 1.5- to 2-fold higher than normal; (3) timing of
post-procedural resumption of warfarin therapy, within
2 days of the procedure; and (4) prothrombin time-
International normalized ratio (PT-INR) at post-procedural
discontinuation of heparin bridging, >therapeutic range.
The score was “1” if the guideline recommendation
was appropriately followed, “0” if the guideline recom-
mendation was not checked, and “-1” if the treatment
was against the guideline recommendation. The ranges
of guideline recommendations for these items were de-
fined as follows on the basis of the 2002 Guidelines by
the American Society of Gastrointestinal Endoscopy
(ASGE) [13] and the 2009 Guidelines by the Japanese
Circulation Society.
Statistical analysis
The chi-square test was used to compare the heparin
bridging group and the control group. The chi-square test
and the logistic regression analysis were used to assess the
association between bleeding and various factors. Factors
with a p-value of <0.5 on the univariate analysis were fur-
ther assessed using the multivariate logistic regression
analysis. A p-value of <0.05 was considered as statistically
significant. All statistical calculations were performed
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using the software JMP® 11 (SAS Institute Inc., Cary, NC,
USA).
Results
Incidences of post-procedural bleeding and thrombosis
According to the questionnaire responses by the 13 par-
ticipating medical institutions in Japan, a total of 245 pa-
tients received HBT in the setting of therapeutic
endoscopy, specifically for upper gastrointestinal treat-
ment in 171 patients and lower gastrointestinal treat-
ment in 74 patients. The controls were 4488 patients
who received upper gastrointestinal treatment and 6614
patients who received lower gastrointestinal treatment
without HBT.
In the HBT group, the mean age was 73.4 ± 8.5 years.
Heparin was a bridge to antiplatelet medication in 111
patients, because this is retrospective study including the
period which was also recommended HBT for antiplate-
let medication by guideline. The type of heparin used for
the bridge was standard unfractionated heparin in 239
patients and low-molecular-weight heparin in 6 patients
(Table 1).
Post-procedural bleeding occurred in 13.5 % (33/245)
patients in the HBT group and 2.7 % (299/11102) in the
control group, with the incidence significantly higher in
the HBT group (p < 0.001). In the case which received
heparin as a bridge to anticoagulant medication, post-
procedural bleeding occurred in 15.7 % (21/134), to
antiplatelet medication, post-procedural bleeding oc-
curred in 10.8 %(12/111). As for the incidence of post-
procedural bleeding by site of endoscopic treatment, that
among patients who received upper gastrointestinal
treatment was 14.1 % (25/171) in the HBT group and
4.5 % (204/4488) in the control group, and that among
patients who received lower gastrointestinal treatment
was 10.8 % (8/74) and 1.4 % (95/6614) respectively, thus
showing similar results to the above (p < 0.001) (Table 2).
Post-procedural bleeding was treated with blood transfu-
sion in 12.1 % (4/33) in the HBT group and 10.7 % (32/
299) in the control group, with no difference between
the two groups. Post-procedural bleeding was manage-
able with either endoscopic intervention or conservative
treatment in all patients in the HBT group, but required
open surgery in 2 of 299 patients in the control group.
No deaths occurred in either group.
Thrombosis occurred in 1 patient each in the HBT
group and the control group who both received upper
gastrointestinal treatment, with no significant difference
between the two groups. The patient in the HBT group
who suffered thrombosis was a 79-year-old male. He had
been receiving oral low-dose aspirin and clopidogrel be-
cause of ischemic heart disease. For a planned gastric
ESD, both drugs were discontinued and administration
of heparin was started, and 2 days later cerebral infarction
occurred. After conservative treatment, the cerebral in-
farction improved, and the patient was once discharged
Table 1 Baseline characteristics of study patients
Upper GI treatment Lower GI treatment Total
HBT patients (number) 171 74 245
Mean age (mean ± S.D.) 74.1 ± 8.6 71.7 ± 8.0 73.4 ± 8.5
Sex (M: F) 142:29 57:17 199:46
Therapy before HBT
anticoagulants 91 43 134
antiplatelets 80 31 111
Antithrobmotic
Single 80 32 112
Multiple 91 42 133
Condition requiring antithrobmotic
Atrial fibrillation 46 22 68
Ischemic heart disease 53 33 86
Deep vein thrombosis 7 1 8
Valve replacement 9 8 17
Arteriosclerosis obliterans 5 4 9
Cerebrovascular disease 46 18 64
Type of heparin used
Unfractionated heparin 171 68 239
LMWH 0 6 6
HBT: heparin bridge therapy, GI: gastrointestinal, LMWH: low molecular- weight heparin. A patient could be counted under more than one condition
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from the hospital 10 days after the onset of cerebral infarc-
tion. On a later day he was re-hospitalized and underwent
ESD on heparin bridging.
The patient in the control group who suffered throm-
bosis was a 72-year-old male. He had been receiving oral
low-dose aspirin alone after coronary artery bypass graft-
ing for angina pectoris. He concurrently had atrial fibril-
lation but was not taking warfarin. Four days after
discontinuation of the low-dose aspirin therapy, cerebral
infarction occurred. After conservative treatment, the
cerebral infarction improved, and ESD was performed
24 days after the onset of cerebral infarction. Both pa-
tients had no further thrombosis at the second interrup-
tion of their long-term antithrombotic therapy.
Used drugs at the time of bleeding
The timing of the occurrence of post-procedural bleed-
ing was more likely post-procedural day 4 or later, com-
pared with the previously reported distribution of the
timing of bleeding after therapeutic endoscopy [14–17].
When bleeding was classified according to the timing of
onset into two types, i.e., early bleeding (defined as
bleeding within 3 post-operative days) and late bleeding
(defined as bleeding from post-operative day 4 to 14),
early bleeding accounted for 33 % and late bleeding for
67 %, showing that late bleeding was more common
(Fig. 2).
Among 21 patients who received heparin as a bridge
to anticoagulant medication and experienced post-
procedural bleeding, the timing of bleeding was analyzed
with the timing classified into five categories from A to
E (Fig. 3). Specifically, the timing “A” was defined as be-
fore post-procedural resumption of heparin, the timing
“B” as after resumption of heparin but before resump-
tion of chronic oral antithrombotic therapy, the timing
“C” as during concomitant use of heparin and anticoagu-
lant medication, the timing “D” as during concomitant
use of three drugs of heparin, anticoagulant medication,
and antiplatelet medication, and the timing “E” as after
the end of heparin bridging and during chronic oral an-
tithrombotic therapy.
Bleeding during the timing “A” accounted for 9.5 %
(2/21), “B” for 28.6 % (6/21), “C” for 23.8 % (5/21), “D”
for 14.3 % (3/21), and “E” for 19.0 % (4/21). In 1 patient
(4.8 %), bleeding occurred after resumption of chronic
oral anticoagulant therapy without resumption of heparin
bridging. Combined timing of “B +C +D,” i.e., bleeding
during use of heparin, accounted for 66.7 %. Bleeding
occurred most commonly during concomitant use of
heparin and anticoagulant medication.
Factors contributing to bleeding
As for factors contributing to bleeding, the univariate
analysis was performed. Next, factors with a p-value
of <0.5 on the univariate analysis assessed by the
multivariate logistic regression analysis(age, the type
Table 2 Incidence of post-procedural bleeding by site of
treatment
HBT group Control group p-value
Total 13.5 % 2.7 % <0.001
(33/245) (299/11102)
Upper gastrointestinal tract 14.1 % 4.5 % <0.001
(25/171) (204/4488)
Lower gastrointestinal tract 10.8 % 1.4 % <0.001
(8/74) (95/6614)
Fig. 2 Early vs. Delayed bleeding. Early, within 3 postprocedural
days; Delayed, day 4–14 after postprocedural day. POD = post
operative day
Fig. 3 Antithrombotic therapy status at bleeding. Among 21
patients who received heparin as a bridge to anticoagulant
medication and experienced post-procedural bleeding, the timing of
bleeding was analyzed with the timing classified into five categories
from A to E according to the antithrombotic therapy status at
bleeding. A, before post-procedural resumption of heparin; B, after
resumption of heparin but before resumption of oral antithrombotic
therapy; C, during concomitant use of heparin and an anticoagulant;
D, during concomitant use of three drugs of heparin, an
anticoagulant, and an antiplatelet drug; E, after the end of heparin
bridging and during oral antithrombotic therapy. The percentages at
the bottom indicate the proportions of patients who had bleeding
during the time periods
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of antithrombotic drugs, number of antithrombotic
drugs, and dose adjustment of heparin for bridging).
Both the univariate analysis and the multivariate analysis
showed that post-procedural bleeding was significantly
more common in patients given bridging therapy with
dose adjustment of heparin according to the APTT mea-
sured (Table 3).
To examine the influence of heparin resumed after
the procedure, similar analyses were performed in a
subgroup of patients on long-term warfarin therapy,
but again dose adjustment of heparin was a signifi-
cant factor.
Compliance score of HBT guideline
Compliance scores of heparin bridging guideline were
calculated among patients who received heparin as a
bridge to anticoagulant medication. The highest possible
total score in each patient was 4. HBT was guideline-
compliant in terms of all assessed items in 14 % of those
who suffered bleeding, compared with as few as 6 % of
those who did not suffer bleeding (Fig. 4). The mean
score was 1.52 in those with bleeding and 0.62 in those
without bleeding, with the score significantly higher in
patients who suffered bleeding (p = 0.01). These results
demonstrated that guideline-compliant HBT was associ-
ated with increased bleeding.
Discussion
More and more patients are now on chronic oral anti-
thrombotic therapy, and antithrombotic management in
the setting of therapeutic endoscopy is an important
issue. Many recent guidelines emphasize the importance
of thrombosis prophylaxis and recommend not to inter-
rupt any antithrombotic therapy in the setting of proce-
dures with a low bleeding risk such as endoscopic
examination and biopsy [2, 3]. Although Asians are con-
sidered more likely to suffer bleeding compared with
Westerners, and the duration of antithrombotic therapy
interruption was described to be likely longer in Eastern
countries than in Western countries [18], in 2012 the
Japan Gastroenterological Endoscopy Society updated its
guideline on perioperative interruption of antithrom-
botic therapy [19] and made it in line with Western
guidelines. Compared with antiplatelet drugs, anticoagu-
lants have a higher bleeding risk and also their interrup-
tion poses a higher thrombotic risk [20–23], so the use
of warfarin requires measurements of blood coagulability
(PT-INR) and the coagulability level needs to be within
the therapeutic range. For therapeutic endoscopy as a
procedure with a high bleeding risk, however, interrup-
tion of antithrombotic therapy for a certain period with
bridging using heparin is recommended, while data have
been scarce on bleeding with HBT.
This survey revealed that the incidence of post-
procedural bleeding was significantly higher in the HBT
group compared with the control group. Bleeding was
common during post-procedural concomitant use of
warfarin and heparin. Compared with typical bleeding
after therapeutic endoscopy, delayed post-procedural
bleeding was more common, for which caution is war-
ranted. Dose adjustment of heparin was a factor contrib-
uting to bleeding, and the incidence of bleeding was
higher with guideline-compliant HBT. In other words,
the data suggest that the risk of bleeding is higher with
proper HBT with maintained coagulability. Thus, HBT
requires further evaluations. The incidence of throm-
bosis did not differ between those given and not given
HBT, and clinicians should keep in mind that the risk of
thrombosis is not zero even with HBT.
While Yoshio et al. documented increased occurrence
of delayed bleeding after gastric ESD on HBT [10], the
present survey in the setting of therapeutic endoscopy,
including both upper gastrointestinal and lower gastro-
intestinal treatments, demonstrated that the incidence of
Table 3 The univariate and multivariate analysis for post-procedural bleeding
Bleeding No bleeding Univariate (p value) Multivariate OR 95 % CI Multivariate (p value)
Age 72.2 ± 8.6 73.6 ± 8.5 0.40 0.26 0.01-9.30 0.45
Sex (M/F) 29/4 170/42 0.71
Anticoagulants vs. Antiplatelet drugsa 21:12 114:98 0.28 1.36 0.61-3.17 0.45
Number of antithrombotic drugs
Multiple vs. singlea
21:12 112:100 0.25 1.88 0.84-4.38 0.12
Type of heparin 32:1 207:5 0.81
Unfractionated heparin vs. LMWH
Dose adjustment of HBT 17:16 36:176 <0.001 5.06 2.29-11.3 <0.001
Adjusted vs. Fixeda
Timing of antithrombotic resumption
Appropriate vs. Inappropriate
16:17 119:93 0.51
OR: odds ratio, CI: confidence interval, LMWH: low molecular- weight heparin, HBT: heparin bridge therapy
aControl in multivariate analysis
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post-procedural bleeding was significantly higher with
HBT than without it. And this finding in the HBT group
of this survey was consistent with a previously published
report that described an increased incidence of delayed
post-procedural bleeding among patients on oral anti-
thrombotic therapy [24].
The present survey revealed that the methods of HBT
varied between different medical institutions, and fully
guideline-compliant HBT was performed in as few as
8 % of the patients. Inappropriate methods of HBT may
not avoid thrombosis. Thrombosis with heparin was re-
ported bridging only in 1 patient in this survey. How-
ever, in light of published literature on fatal thrombosis
during interruption of antithrombotic therapy for endo-
scopic intervention [25], appropriate HBT would be de-
sirable from the viewpoint of thrombosis prophylaxis.
However, HBT guideline is not for bleeding but avoid-
ing thrombosis. The present survey also revealed that
the incidence of bleeding was higher with guideline-
compliant HBT. Also, bleeding was common during
concomitant use of heparin and antithrombotic medica-
tion. In light of published reports describing a lower in-
cidence of bleeding with continuation of warfarin than
with HBT [11, 12] and the anticoagulants is not risk
factor of post endoscopic surgery bleeding [26], the
bleeding risk of HBT requires reassessment. Another lit-
erature report states that new anticoagulants such as
dabigatran and rivaroxaban do not require bridging [27].
Interruption of anticoagulant therapy needs further de-
tailed evaluations, including the use of new anticoagu-
lants as well as continuation of warfarin within the
therapeutic range.
Previous HBT guideline had recommended even for
antiplatelet drugs, not just for the anticoagulant drugs.
This is the retrospective survey including the period of
previous guideline, so many of the patients received
heparin as a bridge to antiplatelet medication. However
bleeding was common even in those given heparin as a
bridge to antiplatelet medication. Recent guidelines rec-
ommend continuation of aspirin or cilostazol therapy
during the peri-procedural period, and do not recom-
mend heparin as a bridge to antiplatelet medication.
However, for patients on both oral anticoagulant and an-
tiplatelet drugs in combination, further studies are re-
quired to determine whether HBT should be performed,
and if HBT is performed, whether concomitant anti-
platelet medication should be given during HBT.
One of the limitation of this study was that this was a
retrospective questionnaire survey. So no background
data could be collected for patients in the control group,
and no comparison was allowed for factors contributing
to bleeding between the HBT group and the control
group. Another limitation was that not all endscopic in-
terventions enrolled.
Despite this limitation, this nationwide multicenter
survey in Japan revealed a higher incidence of bleeding
after therapeutic endoscopy during HBT. The present
survey is also meaningful in that it is the first study
assessing bleeding in both the upper and lower gastro-
intestinal tracts after endoscopy on HBT.
In conclusion, HBT had significant risk of the inci-
dence of post-procedural bleeding compared with con-
trol. The bleeding risk was associated with greater
adherence with guidelines for HBT. Further studies are
required for the use of heparin bridging in those who
are at high risk from interruption of antithrombotic
therapy.
Conclusions
Heparin bridging therapy significantly increased the risk
of post-procedural bleeding compared with the control.
The bleeding risk was associated with greater adherence
with guidelines for heparin bridging therapy.
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